Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. [electronic resource]
Producer: 20150406Description: 1044-52 p. digitalISSN:- 1365-2222
- Adult
- Allergens -- immunology
- Anti-Asthmatic Agents -- pharmacology
- Asthma -- diagnosis
- Bronchial Provocation Tests
- Exhalation
- Forced Expiratory Volume -- drug effects
- Humans
- Indoles -- pharmacology
- Male
- Middle Aged
- Naphthalenes -- pharmacology
- Nitric Oxide -- metabolism
- Receptors, Immunologic -- antagonists & inhibitors
- Receptors, Prostaglandin -- antagonists & inhibitors
- Respiratory Function Tests
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.